A federal district court had ruled in favor of HHS, restricting Vertex's ability to provide fertility preservation services to Medicaid patients.

Vertex Pharmaceuticals’ short interest has dropped by 22.32%, now sitting at 1.74% of its float—Wall Street seems less pessimistic. Short interest reflects how many shares are being bet against and ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Reshma Kewalramani’s journey to become the first female CEO of a large, public U.S. biotechnology company after immigrating ...

Zacks Research has upped the financial bar for Vertex Pharmaceuticals, boosting its 2026 earnings forecast from $16.18 to $16 ...

This was the stock's second consecutive day of gains.

As the U.S. stock market navigates a period of heightened volatility, with major indexes experiencing significant fluctuations amid tariff discussions and economic uncertainties, investors are keenly ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...